Pharmacological Studies with New Liposome-Entrapped Cisplatin Derivatives

Abstract

Therapy for disseminated human cancer is limited by the low degree of tumor selectivity with the antitumor agents currently available. The development of succesful ways to target cytotoxic agents to tumor sites is, therefore, important but, as yet, the approach is still in its infancy. Different types of drug carriers have been considered for that purpose and, among those, liposomes continue to attract significant attention. During the last few years, there has been steady progress in the liposome field, mainly in trying to solve some of the well recognized limitations of lipid vesicles as drug carriers in general, and as carriers of antitumor agents in particular: formulation, scaling up, and tumor targeting properties.